Researchers report 2 cases of a severe B-cell-mediated CNS disease after treatment with alemtuzumab in patients with multiple sclerosis.
Soliris is currently approved to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
More structured MRI reports may aid in the diagnosis of multiple sclerosis.
It is not clear whether CSF CD27 could provide novel or simply complementary prognostic value in clinically isolated syndrome.
The US FDA has approved the first drug for the treatment of spinal muscular atrophy, a genetic disease that often results in premature death.
Patients who received ACE inhibitors showed a slower progression of myocardial fibrosis and fewer cardiovascular events.
Low levels of neonatal vitamin D may be linked with risk of developing multiple sclerosis.
Despite the benefits observed, the improvements still do not represent normal muscle function.
Patients with cancer or an autoimmune disease who underwent surgery were at a greater risk.
Sixty-three percent of patients achieved a complete and stable response that allowed them to discontinue all immunotherapies.
Neurology Advisor Articles
- No Difference in Neurodevelopment in Children Conceived by Assisted Reproduction
- Case Report: Treatment With Alemtuzumab May Prompt Severe CNS Disease
- Treating Pain in Depression May Help Improve Cognition
- The Handoff: Your Week in Neurology News - 1/19/17
- FDA Warns of Implantable Infusion Pumps in MRI